A central theme of the call was the company’s sampling-first approach. Schimmelpennink said the strategy is designed to let patients try the eye drop before purchase, creating “natural self-selection” in which those who experience benefit and choose to buy may be more likely to continue therapy. Management contrasted this with a dynamic it described for Vuity, where patients often had to purchase before trying, potentially contributing to a faster early ramp but also a subsequent drop-off.On persistence, ex ...